Form 990 for tax year 2024
Filed by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC.
Totals
- Total revenue
- $29,101,414
- Total expenses
- $35,604,337
- Contributions and grants received
- $24,100,727
- Grants paid
- $6,080,876
- Program service revenue
- $2,261,716
- Investment income
- $2,238,351
- Other revenue
- $500,620
- Total assets, end of year
- $66,397,148
- Total liabilities, end of year
- $16,374,755
- Net assets or fund balances, end of year
- $50,022,393
- Program services expenses (Part IX)
- $29,021,484
- Management and general expenses
- $1,202,727
- Fundraising expenses
- $5,380,126
- Program service expenses (Part III)
- $29,021,484
Program services were 81.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1e , Government grants (contributions)
$96,720
-
1f , All other contributions, gifts and grants
$24,004,007
-
1g , Noncash contributions included above
$416,902
-
2a , Program service revenue: RESEARCH & CLINICAL TRIALS
total $2,261,716 · related or exempt $2,261,716
-
3 , Investment income
total $1,580,287 · excluded $1,580,287
-
5 , Royalties
total $500,620 · related or exempt $500,620
-
7a , Gross sales of assets other than inventory
securities $100,370,765
-
7b , Less cost or other basis and sales expenses
securities $99,712,701
-
7c , Gain or loss
securities $658,064
-
7d , Net gain or loss
total $658,064 · excluded $658,064
Functional expenses
Part IX, the statement of functional expenses.
-
1 , Grants to domestic organizations and governments
total $5,330,876 · program services $5,330,876
-
3 , Grants to foreign organizations and individuals
total $750,000 · program services $750,000
-
5 , Compensation of officers, directors and key employees
total $3,006,652 · program services $2,340,984 · management and general $244,851 · fundraising $420,817
-
7 , Other salaries and wages
total $6,725,017 · program services $4,377,694 · management and general $650,872 · fundraising $1,696,451
-
8 , Pension plan contributions
total $218,687 · program services $140,736 · management and general $22,923 · fundraising $55,028
-
9 , Other employee benefits
total $711,707 · program services $475,173 · management and general $70,211 · fundraising $166,323
-
10 , Payroll taxes
total $728,372 · program services $501,058 · management and general $67,553 · fundraising $159,761
-
11a , Fees: management
total $273,600 · program services $248,248 · management and general $1,995 · fundraising $23,357
-
11b , Fees: legal
total $332,090 · program services $301,319 · management and general $2,421 · fundraising $28,350
-
11c , Fees: accounting
total $55,750 · program services $50,585 · management and general $406 · fundraising $4,759
-
11g , Fees: other
total $4,690,446 · program services $3,637,126 · management and general $95,118 · fundraising $958,202
-
12 , Advertising and promotion
total $1,674,634 · program services $1,364,548 · management and general $12,210 · fundraising $297,876
-
13 , Office expenses
total $1,445,254 · program services $974,505 · management and general $2,751 · fundraising $467,998
-
14 , Information technology
total $1,378,532 · program services $1,250,798 · management and general $10,051 · fundraising $117,683
-
16 , Occupancy
total $207,168 · program services $187,972 · management and general $1,510 · fundraising $17,686
-
17 , Travel
total $616,552 · program services $396,185 · management and general $10,768 · fundraising $209,599
-
19 , Conferences, conventions and meetings
total $724,594 · program services $365 · fundraising $724,229
-
22 , Depreciation, depletion and amortization
total $446,265 · program services $420,250 · management and general $7,900 · fundraising $18,115
-
23 , Insurance
total $162,738 · program services $147,659 · management and general $1,187 · fundraising $13,892
-
24a , Other expenses: CLINICAL TRIAL/RESEARCH
total $6,125,403 · program services $6,125,403
-
26 , Joint costs (an allocation of the lines above)
total $299,362 · program services $149,251 · management and general $0 · fundraising $150,111
Balance sheet
Part X, book values.
-
1 , Cash, non-interest-bearing
beginning of year $1,373,960 · end of year $2,850,860
-
2 , Savings and temporary cash investments
beginning of year $3,484,634 · end of year $6,236,082
-
3 , Pledges and grants receivable
beginning of year $3,195,258 · end of year $4,254,361
-
4 , Accounts receivable
beginning of year $3,739,397 · end of year $1,327,848
-
9 , Prepaid expenses and deferred charges
beginning of year $715,352 · end of year $487,968
-
10a , Land, buildings and equipment: cost or other basis
$4,356,947
-
10b , Land, buildings and equipment: accumulated depreciation
$2,318,052
-
10c , Land, buildings and equipment, net
beginning of year $2,637,698 · end of year $2,038,895
-
11 , Investments: publicly traded securities
beginning of year $48,157,559 · end of year $28,979,841
-
13 , Investments: program-related
beginning of year $16,363,985 · end of year $19,702,733
-
15 , Other assets
beginning of year $559,789 · end of year $518,560
-
17 , Accounts payable and accrued expenses
beginning of year $19,417,597 · end of year $11,501,089
-
18 , Grants payable
beginning of year $980,000 · end of year $2,407,188
-
19 , Deferred revenue
beginning of year $2,808,555 · end of year $1,974,951
-
25 , Other liabilities
beginning of year $736,056 · end of year $491,527
-
27 , Net assets without donor restrictions
beginning of year $53,786,450 · end of year $46,293,816
-
28 , Net assets with donor restrictions
beginning of year $2,498,974 · end of year $3,728,577
Mission and programs · 2024
Mission
SEE SCHEDULE O
-
THE MMRC IS A NETWORK OF 14 LEADING CANCER CENTERS AND ADDRESSES THREE CRITICAL AREAS OF UNMET NEEDS: HIGH-RISK SMOLDERING MYELOMA, HIGH-RISK UPFRONT TREATMENT FOR SYMPTOMATIC MULTIPLE MYELOMA, AND RELAPSED/REFRACTORY TREATMENT AFTER ANTI-CD38 AND BCMA-DIRECTED THERAPIES.IN 2024, THE MMRF LAUNCHED THE HORIZON CLINICAL TRIALS PROGRAM THROUGH THE MMRC, BEGINNING IN PATIENTS WITH RELAPSED AND REFRACTORY MYELOMA TO OPTIMIZE THE USE OF CURRENTLY AVAILABLE AND NEW TREATMENTS, WITH THE GOAL OF MAXIMIZING EFFICACY WHILE MINIMIZING SIDE EFFECTS. IN NOVEMBER, THE FIRST PATIENT WAS ENROLLED IN THE FIRST ARM OF THE HORIZON CLINICAL TRIALS PROGRAM, HORIZON ONE, WHICH WILL ASSESS DOSING APPROACHES WITH TECVAYLI (TECLISTAMAB). THIS FIRST ARM IS DESIGNED TO DETERMINE WHETHER THIS TREATMENT CAN BE GIVEN LESS FREQUENTLY OR EVEN STOPPED ENTIRELY. THE HORIZON CLINICAL TRIALS PROGRAM USES AN ADAPTIVE PLATFORM DESIGN, WHICH MAKES IT POSSIBLE TO TEST MULTIPLE THERAPIES AT THE SAME TIME, TO DETERMINE THE BEST COMBINATION, SEQUENCE, AND DURATION OF TREATMENT TO IMPROVE PATIENT OUTCOMES. WITH THIS DESIGN AND MULTI-INSTITUTIONAL COOPERATION, HORIZON IS UNIQUELY POSITIONED TO ADDRESS RESEARCH QUESTIONS THAT OTHER TYPES OF TRIALS ARE NOT EQUIPPED TO INVESTIGATE.
Expenses $7,012,440 · Grants $725,000 · Revenue $2,261,716
-
THE MAC PROGRAM PROVIDES $21 MILLION OVER 3 YEARS TO CREATE MULTICENTER TRANSLATIONAL RESEARCH TEAMS ACROSS GLOBAL MEDICAL CENTERS. EACH OF THESE THREE-YEAR MULTICENTER TRANSLATIONAL PROJECTS AIM TO FOSTER COLLABORATION AND ADVANCE COMPELLING HYPOTHESES THAT ARE READY FOR RAPID TESTING IN CLINICAL TRIALS, A CRITICAL STEP IN THE MMRF'S URGENT PURSUIT OF A CURE FOR EACH AND EVERY MYELOMA PATIENT. THE GRANTS ARE FOCUSED ON TWO CRITICAL AREAS OF UNMET NEED: OPTIMIZING FIRST-LINE THERAPY FOR NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA AND IMPROVING IDENTIFICATION OF HIGH-RISK SMOLDERING MULTIPLE MYELOMA (HR SMM), AN EARLY, ASYMPTOMATIC STAGE THAT CAN PROCEED TO ACTIVE MULTIPLE MYELOMA. IN 2024 THE COLLABORATING CENTERS CONTINUED TO MAKE POSITIVE PROGRESS, SHOWING THAT POOLING RESOURCES AND SAMPLES ACROSS A NETWORK OF INSTITUTIONS DRAMATICALLY IMPROVES THE ABILITY TO DRIVE MEANINGFUL RESULTS.
Expenses $5,400,000
-
THE IMMUNE ATLAS PROGRAM IS A COLLABORATION BETWEEN THE MMRF AND FIVE LEADING ACADEMIC MEDICAL CENTERS. THE MMRF CONTINUED TO BUILD OUT THE MMRF IMMUNE ATLAS INITIATIVE (THE "ATLAS"), AN IMMUNE PROFILING AND ANALYTICS PLATFORM USING DATA AND SAMPLES FROM THE COMMPASS STUDY TO GENERATE DATA ON THE ROLE OF PATIENT IMMUNITY IN MYELOMA DISEASE BIOLOGY AND RESPONSE TO THERAPY, AND TO SUPPORT AND SPEED EFFORTS TO MAKE IMMUNOTHERAPY MORE PRECISE FOR MYELOMA PATIENTS. THE ATLAS DESCRIBES THE IMMUNE LANDSCAPE IN MYELOMA AND HOW IT CHANGES THROUGHOUT THE COURSE OF THE DISEASE AND TREATMENT. THIS EFFORT IS A CRITICAL FIRST STEP TO ESTABLISH GUIDELINES AND ALIGNMENT ON HOW IMMUNE DATA IS PRODUCED, PRIORITIZED, AGGREGATED, AND SHARED. AT SCALE, IT HAS THE POTENTIAL TO IDENTIFY NEW IMMUNOLOGIC FACTORS PREDICTIVE OF PATIENT RESPONSE OR RELAPSE TO THERAPY, TO IDENTIFY NEW IMMUNE TARGETS FOR DRUG DEVELOPMENT AND, EVENTUALLY, ENABLE CLINICIANS TO CUSTOMIZE TREATMENTS AND THERAPIES BASED ON AN INDIVIDUAL'S IMMUNE SYSTEM. IN SEPTEMBER 2024, THE MMRF PRESENTED DATA FROM THE ATLAS AT THE 21ST INTERNATIONAL MYELOMA SOCIETY ANNUAL MEETING IN RIO DE JANEIRO, BRAZIL, WHICH REINFORCED THE VALUE OF THE MMRF'S INTEGRATED CLINICAL AND TRANSLATIONAL CAPABILITIES
Expenses $1,069,290
-
BEYOND THE PROGRAM EXPENSES OUTLINED ABOVE, THE MMRF ALSO SUPPORTS A RANGE OF STRATEGIC INITIATIVES ALIGNED WITH ITS BROADER MISSION. THIS INCLUDES A ROBUST PORTFOLIO OF CUTTING-EDGE BASIC SCIENCE RESEARCH AIMED AT IDENTIFYING NEW THERAPEUTIC TARGETS THROUGH GENOMICS AND PROTEOMICS; VALIDATION STUDIES TO EXPLORE PROMISING COMPOUNDS AND TREATMENT COMBINATIONS; AND INNOVATIVE CLINICAL TRIALS FOCUSED ON NOVEL AND COMBINATION THERAPIES.FOUNDED BY PATIENTS, THE MMRF IS DEEPLY COMMITTED TO THOSE IMPACTED BY MULTIPLE MYELOMAPATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF DISTINGUISHES ITSELF THROUGH ITS BOLD AND COLLABORATIVE APPROACH. WE GENERATE, ANALYZE, AND SHARE THE LARGEST, MOST COMPREHENSIVE SET OF HIGH-QUALITY MYELOMA DATA, MAKING IT PUBLICLY AVAILABLE TO ACCELERATE PROGRESS. BY BRINGING TOGETHER THE RIGHT PEOPLE, PROGRAMS, AND TECHNOLOGIES, THE MMRF IS DRIVING THE RAPID DISCOVERY OF CURES FOR EACH AND EVERY PATIENT.
Expenses $15,539,754 · Grants $5,355,876 · Revenue $500,620
As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Kathy GiustiKATHY GIUSTI
FOUNDER & DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Thomas ConheeneyTHOMAS CONHEENEY
CHAIRMAN
- Total calculated
- $0
- Hours/week
- 2
-
Gerald McDougallGERALD MCDOUGALL
VICE CHAIRMAN
- Total calculated
- $0
- Hours/week
- 2
-
Kenneth Anderson MDKENNETH ANDERSON MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Karen AndrewsKAREN ANDREWS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Rodney GilmoreRODNEY GILMORE
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
David LucchinoDAVID LUCCHINO
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Lori Tauber-MarcusLORI TAUBER-MARCUS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Hugh MartinHUGH MARTIN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Susan MarvinSUSAN MARVIN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
William McKiernanWILLIAM MCKIERNAN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Michael MortimerMICHAEL MORTIMER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
David Parkinson MDDAVID PARKINSON MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Marie Pinizzotto MDMARIE PINIZZOTTO MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Adrian RosenkranzADRIAN ROSENKRANZ
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Steve Shak MDSTEVE SHAK MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Kimberly WhiteKIMBERLY WHITE
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Michael AndreiniMICHAEL ANDREINI
PRESIDENT & CEO
- Total calculated
- $492,322
- From this org
- $466,042
- From related orgs
- $0
- Other
- $26,280
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $389,870
- Bonus
- $75,800
- Other
- $372
- Deferred
- $13,800
- Nontaxable benefits
- $12,480
- Filer's total
- $492,322
-
Robert MianiROBERT MIANI
TREASURER & CFO, THRU JUNE 2024
- Total calculated
- $341,915
- From this org
- $328,624
- From related orgs
- $0
- Other
- $13,291
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $124,868
- Bonus
- $56,400
- Other
- $147,356
- Deferred
- $7,292
- Nontaxable benefits
- $5,999
- Filer's total
- $341,915
-
Karen DietzKAREN DIETZ
SECRETARY, CAO & GENERAL COUNSEL
- Total calculated
- $297,717
- From this org
- $259,764
- From related orgs
- $0
- Other
- $37,953
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $207,033
- Bonus
- $31,400
- Other
- $21,331
- Deferred
- $10,920
- Nontaxable benefits
- $27,033
- Filer's total
- $297,717
-
Alan HeitnerALAN HEITNER
TREASURER & CFO, AS OF OCT. 2024
- Total calculated
- $48,231
- From this org
- $46,379
- From related orgs
- $0
- Other
- $1,852
- Hours/week
- 40
-
Anne Quinn YoungANNE QUINN YOUNG
CHIEF MISSION OFFICER
- Total calculated
- $353,857
- From this org
- $335,322
- From related orgs
- $0
- Other
- $18,535
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $280,147
- Bonus
- $39,000
- Other
- $16,175
- Deferred
- $13,537
- Nontaxable benefits
- $4,998
- Filer's total
- $353,857
-
George MulliganGEORGE MULLIGAN
CHIEF SCIENTIFIC OFFICER
- Total calculated
- $387,816
- From this org
- $342,276
- From related orgs
- $0
- Other
- $45,540
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $300,450
- Bonus
- $40,500
- Other
- $1,326
- Deferred
- $13,800
- Nontaxable benefits
- $31,740
- Filer's total
- $387,816
-
Christopher WilliamsCHRISTOPHER WILLIAMS
VP OF ALLIANCE MANAGEMENT
- Total calculated
- $254,973
- From this org
- $218,145
- From related orgs
- $0
- Other
- $36,828
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $196,588
- Bonus
- $7,500
- Other
- $14,057
- Deferred
- $9,140
- Nontaxable benefits
- $27,688
- Filer's total
- $254,973
-
Hearn ChoHEARN CHO
CHIEF MEDICAL OFFICER
- Total calculated
- $212,368
- From this org
- $204,200
- From related orgs
- $0
- Other
- $8,168
- Hours/week
- 32
Schedule J breakdown matched by us
- Base
- $175,025
- Bonus
- $23,500
- Other
- $5,675
- Deferred
- $8,168
- Nontaxable benefits
- $0
- Filer's total
- $212,368
-
Stephanie OestreichSTEPHANIE OESTREICH
MANAGING DIRECTOR, MIF
- Total calculated
- $364,631
- From this org
- $337,767
- From related orgs
- $0
- Other
- $26,864
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $298,622
- Bonus
- $12,200
- Other
- $26,945
- Deferred
- $13,540
- Nontaxable benefits
- $13,324
- Filer's total
- $364,631
-
Katie WozniakKATIE WOZNIAK
VP OF CLINICAL RESEARCH
- Total calculated
- $256,808
- From this org
- $218,889
- From related orgs
- $0
- Other
- $37,919
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $199,180
- Bonus
- $14,000
- Other
- $5,709
- Deferred
- $6,892
- Nontaxable benefits
- $31,027
- Filer's total
- $256,808
-
Greg RubensteinGREG RUBENSTEIN
VP OF MARKETING
- Total calculated
- $250,587
- From this org
- $210,723
- From related orgs
- $0
- Other
- $39,864
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $185,013
- Bonus
- $13,500
- Other
- $12,210
- Deferred
- $8,863
- Nontaxable benefits
- $31,001
- Filer's total
- $250,587
-
Joanne PugliaJOANNE PUGLIA
SR DIRECTOR FINANCE, CONTROLLER
- Total calculated
- $206,732
- From this org
- $197,545
- From related orgs
- $0
- Other
- $9,187
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $174,170
- Bonus
- $13,900
- Other
- $9,475
- Deferred
- $7,864
- Nontaxable benefits
- $1,323
- Filer's total
- $206,732
-
Mark HamiltonMARK HAMILTON
ASSOCIATE DIRECTOR, RESEARCH
- Total calculated
- $256,969
- From this org
- $244,473
- From related orgs
- $0
- Other
- $12,496
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $216,380
- Bonus
- $17,000
- Other
- $11,093
- Deferred
- $7,700
- Nontaxable benefits
- $4,796
- Filer's total
- $256,969
-
Brian HochbergBRIAN HOCHBERG
PRINCIPAL GIFT OFFICER
- Total calculated
- $212,892
- From this org
- $177,081
- From related orgs
- $0
- Other
- $35,811
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $156,134
- Bonus
- $8,000
- Other
- $12,947
- Deferred
- $7,487
- Nontaxable benefits
- $28,324
- Filer's total
- $212,892
-
Heather SteigerHEATHER STEIGER
SR DIRECTOR DIGITAL MARKETING
- Total calculated
- $199,778
- From this org
- $175,571
- From related orgs
- $0
- Other
- $24,207
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $159,577
- Bonus
- $8,400
- Other
- $7,594
- Deferred
- $0
- Nontaxable benefits
- $24,207
- Filer's total
- $199,778
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Compensation committee
- 3 · Form 990 of other organizations
- 3 · Compensation survey or study
- 3 · Approval by the board or compensation committee
- 4a · Severance or change-of-control payment
- 7 · Other non-fixed payments
Answered no
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 8 · Paid under the initial-contract exception
The filer's explanations (Part III)
- PART I, LINE 4A
- ROBERT MIANI, TREASURER & CFO, RECEIVED A SEVERANCE PAYMENT OF $146,800 INCLUDED IN HIS 2024 FORM W-2.
- PART I, LINE 7
- INDIVIDUALS INCLUDED IN SCHEDULE J, PART II RECEIVED A DISCRETIONARY BONUS DURING CALENDAR YEAR 2024, WHICH WAS INCLUDED IN COLUMN B(II) HEREIN AND IN THEIR 2024 FORM W-2, BOX 5, AS TAXABLE MEDICARE WAGES.
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
$1,900,000
SITE INVESTMENT GRANT, IMMUNOTHERAPY, MYELOMA ACCELERATOR CHALLENGE GRANT
-
$1,000,000
SITE INVESTMENT GRANT, PREVENTION
-
BETH ISRAEL DEACONESS MEDICAL CENTER
$860,550
SITE INVESTMENT GRANT, IMMUNOTHERAPY
-
$563,000
SITE INVESTMENT GRANT, IMMUNOTHERAPY
-
$105,000
SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY
-
UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL CENTER
$60,000
FELLOW
-
IMMUNOTHERAPY
-
FELLOW
-
SITE INVESTMENT GRANT
-
SITE INVESTMENT GRANT
The 10 largest by cash amount. The API serves every itemized grant.
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 0
- Employees, agents and contractors (line 3c)
- 0
- Expenditures and investments (line 3c)
- $2,792,954
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) | 0 | 0 | GRANTMAKING | — | $750,000 |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | INVESTMENTS | — | $1,042,959 |
| NORTH AMERICA | 0 | 0 | INVESTMENTS | — | $999,995 |
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) | $750,000 | WIRE | $0 | — | — |
- Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
- 1
- Other grantees (Part II line 3)
- 0
- Transferred property to a foreign corporation during the year (line 1)
- Yes
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- Yes
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Taxable family on this return
Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.
Disregarded entities
Part I: entities that legally are the filer and file no return of their own.
-
MYELOMA INVESTMENT FUND LLC
VENTURE PHILANTHROPY FUND · DE · income $1,301,178 · assets $22,403,440
Directly controlled by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC
-
MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC
FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCH · CT · income $7,842,093 · assets $1,446,240
Directly controlled by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 15 October 2025
- IRS schema version
- 2024v5.2
- Source object
- 202512889349301411
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.